Drug-induced nephrotoxicity Medical Services in China

Drug-induced nephrotoxicity refers to acute or chronic kidney injury caused by exposure to pharmacologic agents—either therapeutic doses of commonly prescribed medications or overdose/abuse scenarios. It is a leading cause of hospital-acquired acute kidney injury (AKI), accounting for approximately 19–25% of all AKI cases in inpatient settings globally. Pathophysiologically, nephrotoxicity arises through multiple mechanisms: direct tubular epithelial cell injury (e.g., aminoglycosides, cisplatin), intrarenal vasoconstriction and ischemia (e.g., NSAIDs, calcineurin inhibitors), crystal-induced tubular obstruction (e.g., acyclovir, sulfonamides, methotrexate), immune-mediated interstitial nephritis (e.g., PPIs, beta-lactams, diuretics), or glomerular damage (e.g., pamidronate, ifosfamide). Risk factors are multifactorial and include advanced age (>65 years), preexisting chronic kidney disease (CKD), diabetes mellitus, hypertension, heart failure, volume depletion, concurrent use of multiple nephrotoxic agents (e.g., dual RAAS blockade + NSAID), and genetic polymorphisms affecting drug metabolism (e.g., GSTM1 null genotype increasing cisplatin toxicity). Epidemiologically, incidence varies widely by clinical setting: among hospitalized adults, it affects 3–10% of patients receiving high-risk drugs; in oncology units, up to 30% of patients receiving platinum-based chemotherapy develop some degree of renal impairment. Critically, early recognition remains challenging due to nonspecific symptoms—including fatigue, nausea, decreased urine output, peripheral edema, and confusion—which often overlap with underlying illness or comorbidities. Untreated or severe cases may progress to dialysis-dependent kidney failure, prolonged hospitalization, or increased 90-day mortality (up to 25% in ICU-associated nephrotoxic AKI). Quality of life is significantly compromised: patients report persistent fatigue, cognitive slowing, sleep disturbances, anxiety about long-term kidney health, and limitations in physical activity and employment. Those requiring dialysis face substantial psychosocial burden, dietary restrictions, frequent clinic visits, and reduced health-related quality of life scores (measured by KDQOL-SF) comparable to end-stage heart failure. Importantly, many cases are preventable through vigilant medication review, dose adjustment per eGFR, hydration optimization, avoidance of drug combinations with synergistic toxicity, and real-time monitoring of serum creatinine and urinary biomarkers (e.g., NGAL, KIM-1) in high-risk populations.

Drug-induced nephrotoxicity refers to acute or chronic kidney injury resulting from direct toxic effects, immune-mediated mechanisms, or hemodynamic alterations triggered by pharmacologic agents. It accounts for approximately 19–25% of all cases of acute kidney injury (AKI) in hospitalized adults and is a leading cause of iatrogenic renal dysfunction. Common causes include aminoglycoside antibiotics (e.g., gentamicin, tobramycin), which accumulate in proximal tubular cells, inducing mitochondrial dysfunction and oxidative stress; platinum-based chemotherapeutics (e.g., cisplatin), which cause DNA crosslinking and apoptosis in tubular epithelial cells; nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit renal cyclooxygenase-1 and -2, reducing vasodilatory prostaglandins (PGE₂, PGI₂) and compromising afferent arteriolar tone—particularly in states of intravascular volume depletion or heart failure; radiocontrast media, which induce medullary hypoxia via vasoconstriction, direct tubular toxicity, and reactive oxygen species generation; and calcineurin inhibitors (e.g., cyclosporine, tacrolimus), which cause preglomerular vasoconstriction, endothelial injury, and progressive interstitial fibrosis with chronic use. Other notable agents include antivirals (e.g., tenofovir disoproxil fumarate, acyclovir—especially when precipitated as intratubular crystals), antimycobacterials (e.g., rifampin-associated interstitial nephritis), and newer immunomodulators (e.g., checkpoint inhibitors linked to immune-mediated glomerulonephritis and tubulointerstitial nephritis). Triggers often involve pharmacokinetic or pharmacodynamic perturbations: rapid intravenous administration of nephrotoxins, concomitant use of multiple nephrotoxic agents (e.g., NSAID + ACE inhibitor + diuretic), abrupt volume contraction (e.g., postoperative fasting, gastrointestinal losses, diuretic overuse), sepsis-induced renal hypoperfusion, or uncontrolled hypertension exacerbating endothelial injury. Risk factors are multifactorial and hierarchical. Advanced age (>65 years) confers reduced renal reserve, diminished drug clearance, and increased susceptibility to ischemic and toxic insults. Preexisting chronic kidney disease (CKD), particularly with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m², markedly amplifies risk due to impaired drug elimination and heightened tubular vulnerability. Diabetes mellitus and cardiovascular disease promote microvascular dysfunction and endothelial dysregulation, potentiating NSAID- and contrast-induced injury. Volume depletion—whether from dehydration, congestive heart failure, cirrhosis, or nephrotic syndrome—compromises renal perfusion pressure and augments tubular reabsorption of toxins. Concomitant use of renin-angiotensin-aldosterone system (RAAS) inhibitors (ACEIs/ARBs) or diuretics further impairs autoregulation and sodium delivery, increasing susceptibility to NSAID- and contrast-induced AKI. Genetic factors contribute significantly to interindividual variability in susceptibility. Polymorphisms in genes encoding drug-metabolizing enzymes—including CYP2C9, CYP3A4, and N-acetyltransferase 2 (NAT2)—alter systemic exposure and renal accumulation of nephrotoxins. Variants in solute carrier transporters (e.g., SLC22A2/OCT2) influence cisplatin uptake into proximal tubules; the rs316019 SNP in OCT2 is associated with higher cisplatin nephrotoxicity risk. Polymorphisms in antioxidant defense genes (e.g., GSTM1 null genotype, SOD2 Val16Ala) impair detoxification of reactive oxygen species generated by aminoglycosides or cisplatin. HLA class II alleles (e.g., HLA-DRB1*04:05, HLA-DQB1*04:01) are linked to NSAID- and proton-pump inhibitor–induced interstitial nephritis. Environmental factors also modulate risk: prolonged exposure to high ambient temperatures increases insensible fluid loss and predisposes to prerenal azotemia during nephrotoxin exposure; occupational exposure to heavy metals (e.g., lead, cadmium) or organic solvents may synergize with pharmaceutical nephrotoxins via shared pathways of oxidative stress and mitochondrial injury; and socioeconomic determinants—including limited access to outpatient monitoring, delayed presentation, and polypharmacy in underserved populations—contribute to preventable nephrotoxic events. Importantly, many cases are preventable through vigilant risk stratification, dose adjustment per eGFR, hydration protocols (e.g., IV isotonic saline before contrast), avoidance of high-risk combinations, and therapeutic drug monitoring where applicable (e.g., aminoglycosides, vancomycin). Early recognition—via serial serum creatinine, urine output assessment, and novel biomarkers (e.g., NGAL, KIM-1)—remains critical to mitigate irreversible structural damage and progression to chronic kidney disease.

Drug-induced nephrotoxicity refers to acute or chronic kidney injury resulting from direct toxic effects, immune-mediated mechanisms, or hemodynamic alterations triggered by pharmacologic agents. It is a leading cause of iatrogenic acute kidney injury (AKI), accounting for approximately 19–25% of all hospitalized AKI cases, and contributes significantly to morbidity, prolonged hospitalization, dialysis dependence, and increased mortality—particularly in critically ill, elderly, or chronically ill patients with preexisting renal impairment, diabetes, or heart failure.

Early symptoms are often subtle and nonspecific, reflecting the kidney’s substantial functional reserve. Patients may report mild fatigue, decreased energy, or generalized malaise. Subtle reductions in urine output (oliguria) may be noted—though many cases present as nonoliguric AKI, especially with aminoglycosides or contrast media. Mild peripheral edema, particularly periorbital or ankle swelling, may appear due to early sodium and water retention. Some individuals experience transient nausea or anorexia without overt gastrointestinal pathology. Importantly, serum creatinine may remain within normal limits initially despite significant tubular injury; thus, early biomarkers such as urinary neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), or interleukin-18 may rise before creatinine elevation—though these are not routinely used in clinical practice outside research or high-risk procedural settings.

Typical symptoms emerge as glomerular filtration rate (GFR) declines by ≥25–50%. Oliguria (<400 mL/day in adults) becomes more pronounced, especially in proximal tubular necrosis induced by cisplatin or aminoglycosides. Patients commonly develop progressive fatigue, lethargy, and confusion attributable to uremic toxin accumulation and electrolyte disturbances. Hypertension may manifest or worsen secondary to volume expansion and activation of the renin-angiotensin-aldosterone system (RAAS). Dyspnea on exertion or orthopnea may occur due to pulmonary congestion from fluid overload. In interstitial nephritis—commonly caused by NSAIDs, PPIs, or antibiotics like beta-lactams—patients frequently present with low-grade fever, arthralgias, and a pruritic maculopapular rash, though rash is absent in up to 30% of biopsy-proven cases. Urinalysis typically reveals sterile pyuria, mild proteinuria (<2 g/day), and eosinophiluria (detected via Hansel or Wright stain), although eosinophiluria lacks sensitivity and specificity.

Accompanying symptoms reflect systemic involvement and drug-specific toxicity. With NSAID-induced injury, patients may exhibit worsening hypertension, heart failure decompensation, or hyperkalemia due to suppressed renin release and reduced aldosterone synthesis. Vancomycin or aminoglycoside toxicity may coexist with ototoxicity (tinnitus, hearing loss) or neuromuscular irritability (paresthesias, muscle cramps) secondary to hypocalcemia or hypomagnesemia. Contrast-induced nephropathy often follows angiographic procedures and presents with rising creatinine within 24–72 hours, typically peaking at 3–5 days, without systemic inflammatory signs. Calcineurin inhibitor toxicity (e.g., cyclosporine, tacrolimus) may feature new-onset tremor, headache, or posterior reversible encephalopathy syndrome (PRES) alongside renal vasoconstriction and thrombotic microangiopathy (TMA)-like features. Methotrexate-induced crystal nephropathy may cause acute flank pain and gross hematuria due to intratubular precipitation.

Complications arise from progressive renal dysfunction and metabolic derangements. Hyperkalemia (>5.5 mmol/L) can precipitate life-threatening cardiac arrhythmias—including peaked T-waves, ventricular fibrillation, or asystole. Metabolic acidosis (serum bicarbonate <22 mmol/L) leads to Kussmaul respirations and impaired cellular metabolism. Volume overload may culminate in acute pulmonary edema or hypertensive emergency. Uremic pericarditis—characterized by pleuritic chest pain, pericardial friction rub, and ECG changes (diffuse ST elevation)—occurs in severe, untreated cases. Chronic exposure to nephrotoxins (e.g., chronic NSAID use, aristolochic acid-containing herbs) may lead to analgesic nephropathy or Balkan endemic nephropathy, manifesting as chronic interstitial fibrosis, tubular atrophy, and progressive CKD with bland urinalysis and minimal proteinuria. Rare but severe complications include cortical necrosis (especially with vasopressors or disseminated intravascular coagulation), TMA (associated with quinine, mitomycin C, or calcineurin inhibitors), and renal cortical scarring.

Diagnosis relies on a high index of suspicion, temporal correlation between drug exposure and renal dysfunction, and exclusion of alternative etiologies. Serum creatinine and estimated GFR should be monitored serially—particularly before and after administration of high-risk agents (e.g., IV contrast, aminoglycosides, vancomycin). Urinalysis is essential: granular or muddy brown casts suggest acute tubular necrosis; sterile pyuria and eosinophils support interstitial nephritis; crystalluria may indicate methotrexate or sulfadiazine toxicity. Quantitative urine studies—including fractional excretion of sodium (FeNa <1% in prerenal or NSAID-induced vasoconstriction; >2% in ATN), urine sodium, and osmolality—help differentiate functional from structural injury. Renal ultrasound is performed to exclude obstruction and assess kidney size and echogenicity (increased echogenicity suggests chronic damage or infiltrative disease). Kidney biopsy remains the gold standard for definitive diagnosis in ambiguous cases—especially when systemic vasculitis, glomerulonephritis, or unexplained interstitial inflammation is suspected—but is rarely indicated acutely unless there is diagnostic uncertainty, atypical presentation, or failure to improve after drug withdrawal. Therapeutic drug monitoring (e.g., vancomycin troughs, aminoglycoside peak/trough levels) aids in identifying supratherapeutic exposure.

Differential diagnosis must rigorously exclude other causes of AKI. Prerenal azotemia (e.g., hypovolemia, heart failure, sepsis) mimics early nephrotoxicity but improves rapidly with volume resuscitation and lacks urinary sediment abnormalities. Postrenal obstruction (e.g., stones, prostate enlargement) presents with abrupt anuria or fluctuating output and is confirmed by hydronephrosis on ultrasound. Glomerulonephritides (e.g., ANCA-associated vasculitis, lupus nephritis) often feature active urinary sediment (dysmorphic RBCs, RBC casts), systemic manifestations (rash, arthralgia, pulmonary hemorrhage), and serologic abnormalities (ANCA, anti-dsDNA, low complement). Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) show microangiopathic hemolytic anemia, thrombocytopenia, and schistocytes on peripheral smear—distinct from most drug-induced tubulointerstitial injuries. Malignancy-related AKI (e.g., myeloma cast nephropathy, lymphomatous infiltration) requires serum/urine electrophoresis or imaging. Finally, sepsis-associated AKI may coexist with drug exposure but is distinguished by systemic inflammatory response, positive cultures, and cytokine-driven endothelial injury rather than direct tubular toxicity.

Drug-induced nephrotoxicity (DIN) refers to acute or chronic kidney injury resulting from exposure to pharmacologic agents with inherent renal toxicity. Common culprits include aminoglycosides, vancomycin, amphotericin B, nonsteroidal anti-inflammatory drugs (NSAIDs), calcineurin inhibitors (e.g., cyclosporine, tacrolimus), cisplatin, radiocontrast media, and certain antivirals (e.g., tenofovir disoproxil fumarate). Early recognition—via serum creatinine trends, estimated glomerular filtration rate (eGFR) decline, urinary biomarkers (e.g., NGAL, KIM-1), and urinalysis—is critical to prevent irreversible tubulointerstitial fibrosis or glomerular damage. Management is stratified into conservative, pharmacologic, and procedural interventions, with emphasis on discontinuation of the offending agent as the cornerstone of therapy.

Conservative treatment constitutes the first-line and most universally applicable approach. It centers on immediate cessation of the nephrotoxic drug, followed by rigorous hemodynamic optimization. Intravascular volume status must be carefully assessed and corrected: isotonic crystalloids (e.g., 0.9% saline or balanced solutions such as lactated Ringer’s) are administered judiciously to maintain euvolemia—avoiding both hypovolemia (which exacerbates renal hypoperfusion) and fluid overload (which may precipitate pulmonary edema in compromised patients). Blood pressure targets should aim for mean arterial pressure ≥65 mmHg, with cautious use of vasopressors (e.g., norepinephrine) only if septic or cardiogenic shock coexists. Electrolyte imbalances—including hyperkalemia, metabolic acidosis, and hyponatremia—are managed per standard nephrology protocols: calcium gluconate for cardiac membrane stabilization, insulin-dextrose and sodium bicarbonate for acute hyperkalemia, and oral or IV sodium bicarbonate only in severe metabolic acidosis (pH <7.15) with preserved renal perfusion. Nutritional support emphasizes low-protein, low-sodium, and potassium-restricted diets during acute injury, transitioning to adequate protein intake (0.8–1.0 g/kg/day) during recovery to mitigate catabolism. Close monitoring of urine output, daily weights, serial creatinine, electrolytes, and fractional excretion of sodium (FeNa) guides ongoing management.

Pharmacologic interventions are adjunctive and agent-specific. For NSAID-induced afferent arteriolar vasoconstriction, withdrawal alone often suffices; however, in high-risk patients (e.g., those with heart failure or cirrhosis), short-term low-dose loop diuretics may be considered cautiously. In contrast, cisplatin nephrotoxicity is mitigated prophylactically with aggressive intravenous hydration (3–4 L/day pre- and post-infusion) and magnesium supplementation; amifostine—a thiol-based cytoprotectant—may be used selectively in oncology settings despite limited evidence for routine adoption. For aminoglycoside toxicity, once-daily dosing with therapeutic drug monitoring (peak/trough levels) reduces accumulation in proximal tubular cells. Vancomycin-induced nephrotoxicity is minimized via area-under-the-curve (AUC)-guided dosing rather than trough-only monitoring. In contrast-induced nephropathy (CIN), intravenous isotonic sodium bicarbonate or sodium chloride infusion remains first-line prophylaxis; while N-acetylcysteine (NAC) has shown inconsistent benefit in meta-analyses, it is still employed in high-risk populations (eGFR <45 mL/min/1.73m², diabetes, multiple myeloma) due to its antioxidant properties. Novel agents under investigation include endothelin receptor antagonists and SGLT2 inhibitors (e.g., empagliflozin), which demonstrate renoprotective effects in early-phase trials but lack definitive DIN-specific indications.

Surgical treatment plays a minimal role in DIN, as it is rarely indicated for the nephrotoxic process itself. However, urgent renal replacement therapy (RRT) may be required in cases of life-threatening complications: severe hyperkalemia (K⁺ >6.5 mmol/L with ECG changes), uremic encephalopathy or pericarditis, refractory fluid overload, or metabolic acidosis unresponsive to medical therapy. Modalities include intermittent hemodialysis (IHD), continuous renal replacement therapy (CRRT), or prolonged intermittent RRT (PIRRT), selected based on hemodynamic stability, ICU availability, and clinical urgency. CRRT is preferred in critically ill, unstable patients due to superior hemodynamic tolerance and precise fluid control. Surgical nephrectomy or renal artery intervention is not indicated for DIN unless coincident pathology exists (e.g., obstructive uropathy secondary to drug-induced crystalluria—such as with sulfadiazine or acyclovir—which may require ureteral stenting or nephrostomy). Lithotripsy or endoscopic stone removal may be necessary for obstructive nephropathy caused by drug crystals, though this is exceedingly rare in contemporary practice with improved hydration and drug selection.

China offers distinct advantages in the multidisciplinary management of DIN. First, integrated Traditional Chinese Medicine (TCM)–Western medicine protocols—endorsed by the National Health Commission—are increasingly incorporated into nephrology care. Evidence-based herbal formulations (e.g., Huangqi decoction, containing Astragalus membranaceus) have demonstrated anti-fibrotic and anti-inflammatory effects in preclinical models of tubular injury and are used adjunctively to support renal repair during recovery. Second, China’s national electronic health record system enables real-time pharmacovigilance: the China Adverse Drug Reaction Monitoring Center (CADRMC) rapidly identifies emerging DIN signals (e.g., recent alerts on herbal nephrotoxins like aristolochic acid analogues), facilitating nationwide safety alerts and prescribing guideline updates. Third, advanced diagnostic infrastructure—including widespread access to urinary biomarker assays (NGAL, cystatin C), point-of-care ultrasound for renal resistive index assessment, and AI-assisted eGFR trajectory modeling—is available even in tier-2 and tier-3 hospitals, enabling earlier detection and risk stratification. Finally, standardized clinical pathways for DIN—developed by the Chinese Society of Nephrology—ensure consistent application of KDIGO-aligned protocols across urban and rural centers.

Recovery advice emphasizes patient empowerment and longitudinal surveillance. Patients must receive explicit written documentation of the causative drug(s), with clear avoidance instructions and pharmacist-led medication reconciliation at discharge. Follow-up includes serum creatinine and eGFR every 1–2 weeks initially, then monthly until stabilization, with annual monitoring thereafter—even after apparent full recovery—to detect late-onset interstitial fibrosis. Lifestyle counseling focuses on hydration (1.5–2.0 L/day unless contraindicated), avoidance of over-the-counter NSAIDs and herbal supplements without nephrology consultation, and blood pressure control (<130/80 mmHg). Vaccination against influenza and pneumococcus is recommended to reduce infection-related AKI triggers. For patients with residual CKD, referral to a certified renal dietitian for personalized nutrition planning and enrollment in structured self-management programs (e.g., China’s ‘Healthy Kidney’ community initiative) improves long-term adherence and outcomes. Importantly, psychological support is integrated, as DIN-related anxiety about future medication use and chronic disease progression is common and associated with reduced health-related quality of life.